Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
$1.65
-3.5%
$1.58
$1.03
$2.41
$51.47M-0.53420,074 shs96,492 shs
Ceapro Inc. stock logo
CRPOF
Ceapro
$0.17
$0.17
$0.11
$0.40
$13.31M1.4715,466 shsN/A
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
$0.23
-5.6%
$0.32
$0.23
$0.71
$42.89M0.8312,932 shs31,783 shs
RZLTD
Rezolute
$6.55
+0.8%
$5.13
$16.00
$24.05
$55.14M4.634,788 shs483,650 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
+1.18%+16.33%0.00%-6.56%-6.04%
Ceapro Inc. stock logo
CRPOF
Ceapro
0.00%0.00%0.00%0.00%0.00%
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
-6.12%-8.53%-25.33%-25.67%-59.54%
RZLTD
Rezolute
0.00%+11.88%+20.59%+82.07%+53.30%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
2.9296 of 5 stars
3.55.00.00.02.80.00.6
Ceapro Inc. stock logo
CRPOF
Ceapro
N/AN/AN/AN/AN/AN/AN/AN/A
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
N/AN/AN/AN/AN/AN/AN/AN/A
RZLTD
Rezolute
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
3.00
Buy$4.50172.73% Upside
Ceapro Inc. stock logo
CRPOF
Ceapro
0.00
N/AN/AN/A
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
0.00
N/AN/AN/A
RZLTD
Rezolute
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CRPOF, ATNM, PYRGF, and RZLTD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2025
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
(Data available from 8/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
N/AN/AN/AN/A$1.31 per shareN/A
Ceapro Inc. stock logo
CRPOF
Ceapro
$7.14M1.86$0.06 per share2.74$0.32 per share0.53
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
$9.14M4.69N/AN/A($0.01) per share-22.87
RZLTD
Rezolute
N/AN/AN/AN/A$1.24 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
-$48.82M-$1.31N/AN/AN/AN/A-100.85%-47.89%N/A
Ceapro Inc. stock logo
CRPOF
Ceapro
-$3.49M-$0.06N/AN/A-69.60%-20.30%-18.07%N/A
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
-$21.12M-$0.03N/AN/A-115.14%N/A-60.81%N/A
RZLTD
Rezolute
-$20.33MN/A0.00N/AN/A-153.46%-111.71%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
N/AN/AN/AN/AN/A
Ceapro Inc. stock logo
CRPOF
Ceapro
N/AN/AN/AN/AN/A
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
N/AN/AN/AN/AN/A
RZLTD
Rezolute
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
N/A
10.25
10.25
Ceapro Inc. stock logo
CRPOF
Ceapro
N/A
11.00
7.72
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
N/A
0.60
0.50
RZLTD
Rezolute
N/A
3.26
3.26

Institutional Ownership

CompanyInstitutional Ownership
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
27.50%
Ceapro Inc. stock logo
CRPOF
Ceapro
N/A
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
0.03%
RZLTD
Rezolute
N/A

Insider Ownership

CompanyInsider Ownership
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
6.00%
Ceapro Inc. stock logo
CRPOF
Ceapro
N/A
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
47.68%
RZLTD
Rezolute
4.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
3031.20 million29.32 millionOptionable
Ceapro Inc. stock logo
CRPOF
Ceapro
N/A78.29 millionN/ANot Optionable
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
90187.53 million96.34 millionNo Data
RZLTD
Rezolute
238.42 millionN/ANot Optionable

Recent News About These Companies

America/Resolute Time zone • Current Time in Resolute
Rezolute (RZLT) Earnings Dates & Reports
Xilio Development Inc (XLO)
Systems Ltd.
Rezolute (RZLT) Gets a Buy from H.C. Wainwright

New MarketBeat Followers Over Time

Media Sentiment Over Time

Actinium Pharmaceuticals stock logo

Actinium Pharmaceuticals NYSE:ATNM

$1.65 -0.06 (-3.51%)
Closing price 04:00 PM Eastern
Extended Trading
$1.63 -0.02 (-1.21%)
As of 06:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

Ceapro stock logo

Ceapro OTCMKTS:CRPOF

$0.17 0.00 (0.00%)
As of 06/6/2024

Ceapro Inc., a biotechnology company, engages in the development and marketing of health and wellness products and technology relating to plant extracts in the United States, Germany, China, Canada, and internationally. The company is involved in the development of proprietary extraction technologies and the application of these technologies to the production, development, and commercialization of active ingredients, such as oat beta glucan and avenanthramides, which are derived from oats and other renewable plant resources for healthcare and cosmetic industries. It also offers natural active ingredients, including oat powder, oat oil, oat peptides, and lupin peptides to the personal care, cosmetic, medical, and animal health industries; anti-aging skincare products to the cosmeceutical industries; and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner. The company has a research collaboration with the Angiogenesis Foundation. The company was incorporated in 1997 and is headquartered in Edmonton, Canada.

PyroGenesis Canada stock logo

PyroGenesis Canada NASDAQ:PYRGF

$0.23 -0.01 (-5.61%)
As of 03:52 PM Eastern

PyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada.

Rezolute OTCMKTS:RZLTD

$6.55 +0.05 (+0.77%)
As of 08/18/2025

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for rare and metabolic diseases in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also develops RZ402, a small molecule plasma kallikrein inhibitor, which is in preclinical stage for the treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.